CN104023733A - 癌症的免疫原性治疗 - Google Patents

癌症的免疫原性治疗 Download PDF

Info

Publication number
CN104023733A
CN104023733A CN201280059421.0A CN201280059421A CN104023733A CN 104023733 A CN104023733 A CN 104023733A CN 201280059421 A CN201280059421 A CN 201280059421A CN 104023733 A CN104023733 A CN 104023733A
Authority
CN
China
Prior art keywords
immunomodulator
cancer
tumor
therapy
cell death
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280059421.0A
Other languages
English (en)
Chinese (zh)
Inventor
查尔斯·艾科
赛特温德·穆旦
约翰·格兰奇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Heroes And Models' Degree Human Relations Medical Co
Original Assignee
Heroes And Models' Degree Human Relations Medical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heroes And Models' Degree Human Relations Medical Co filed Critical Heroes And Models' Degree Human Relations Medical Co
Publication of CN104023733A publication Critical patent/CN104023733A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Radiation-Therapy Devices (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201280059421.0A 2011-12-02 2012-12-03 癌症的免疫原性治疗 Pending CN104023733A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1120779.2 2011-12-02
GBGB1120779.2A GB201120779D0 (en) 2011-12-02 2011-12-02 Cancer therapy
PCT/GB2012/052992 WO2013079980A1 (en) 2011-12-02 2012-12-03 Immunogenic treatment of cancer

Publications (1)

Publication Number Publication Date
CN104023733A true CN104023733A (zh) 2014-09-03

Family

ID=45509083

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280059421.0A Pending CN104023733A (zh) 2011-12-02 2012-12-03 癌症的免疫原性治疗

Country Status (15)

Country Link
US (4) US20140356397A1 (cg-RX-API-DMAC7.html)
EP (1) EP2785361B1 (cg-RX-API-DMAC7.html)
JP (1) JP6085611B2 (cg-RX-API-DMAC7.html)
KR (1) KR20140097419A (cg-RX-API-DMAC7.html)
CN (1) CN104023733A (cg-RX-API-DMAC7.html)
AU (1) AU2012343536B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014012880A2 (cg-RX-API-DMAC7.html)
CA (1) CA2857429A1 (cg-RX-API-DMAC7.html)
GB (1) GB201120779D0 (cg-RX-API-DMAC7.html)
IL (1) IL232890A0 (cg-RX-API-DMAC7.html)
IN (1) IN2014MN00955A (cg-RX-API-DMAC7.html)
MX (1) MX2014006511A (cg-RX-API-DMAC7.html)
RU (1) RU2014121335A (cg-RX-API-DMAC7.html)
SG (1) SG11201402396XA (cg-RX-API-DMAC7.html)
WO (1) WO2013079980A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114367060A (zh) * 2022-01-13 2022-04-19 深圳大学 激光交变电场联合治疗仪

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11963716B2 (en) 2010-07-19 2024-04-23 Emblation Limited Apparatus and method for the treatment of dermatological diseases or conditions
GB201120779D0 (en) * 2011-12-02 2012-01-11 Immodulon Therapeutics Ltd Cancer therapy
GB201308325D0 (en) * 2013-05-09 2013-06-19 Immodulon Therapeutics Ltd Cancer Therapy
FI3077041T3 (fi) 2013-12-05 2024-10-16 Rfemb Holdings Llc Syövän immunoterapia radiotaajuisella sähköisellä solukalvon hajotuksella (rf-emb)
GB201322725D0 (en) * 2013-12-20 2014-02-05 Immodulon Therapeutics Ltd Cancer therapy
US11141216B2 (en) 2015-01-30 2021-10-12 Immunsys, Inc. Radio-frequency electrical membrane breakdown for the treatment of high risk and recurrent prostate cancer, unresectable pancreatic cancer, tumors of the breast, melanoma or other skin malignancies, sarcoma, soft tissue tumors, ductal carcinoma, neoplasia, and intra and extra luminal abnormal tissue
PL3319635T3 (pl) * 2015-06-24 2021-10-25 Immodulon Therapeutics Limited Inhibitor punktu kontrolnego i prątek całokomórkowy do stosowania w terapii nowotworowej
RU2596505C1 (ru) * 2015-07-02 2016-09-10 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский радиологический центр" Министерства здравоохранения Российской Федерации (ФГБУ "НМИРЦ" Минздрава России) Способ лечения онкологических больных цитотоксическими лимфоцитами
US10478194B2 (en) 2015-09-23 2019-11-19 Covidien Lp Occlusive devices
CA3011460A1 (en) 2016-01-15 2017-07-20 Rfemb Holdings, Llc Immunologic treatment of cancer
RU2018136347A (ru) * 2016-04-14 2020-05-14 Фелдрайх Каро Руиз Аб Аппарат для радиационной терапии, включающий модуль ионизации и источник ультрафиолетового света
CA3058380A1 (en) 2017-03-28 2018-10-04 Emblation Limited Stenosis treatment
US11173325B2 (en) 2017-07-21 2021-11-16 Varian Medical Systems, Inc. Methods of use of ultra-high dose rate radiation and therapeutic agent
RU2664597C1 (ru) * 2017-12-12 2018-08-21 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) Способ комбинированного лечения больных первично операбельным и местно-распространенным неоперабельным раком молочной железы
MA54399A (fr) 2018-12-03 2021-10-13 Fusion Pharmaceuticals Inc Radioimmunoconjugués et polythérapie à base d'inhibiteur de point de contrôle
US20220098578A1 (en) * 2019-01-31 2022-03-31 Bar Ilan University Neoantigens created by aberrant-induced splicing and uses thereof in enhancing immunotherapy
US20230045616A1 (en) * 2019-12-27 2023-02-09 Nonprofit Organization North East Japan Study Group Cancer treatment method and medicine
EP4376945A1 (en) * 2021-07-27 2024-06-05 Immodulon Therapeutics Limited A mycobacterium for use in cancer therapy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003049751A1 (en) * 2001-12-10 2003-06-19 Bakulesh Mafatlal Khamar The process of manufacturing a pharmaceutical composition useful for management of cancer
EP2010216A2 (en) * 2006-03-24 2009-01-07 Donald L. Morton Mycobacterial immunotherapy for cancer treatment

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5207223A (en) 1990-10-19 1993-05-04 Accuray, Inc. Apparatus for and method of performing stereotaxic surgery
EP0556248B1 (en) * 1990-11-08 1997-06-25 University College London Mycobacterium as adjuvant for antigens
US5458125A (en) 1994-01-28 1995-10-17 Board Of Directors Of The Leland Standford Jr. University Treatment planning method and apparatus for radiosurgery and radiation therapy
WO2000064476A2 (en) 1999-04-23 2000-11-02 Qlt Inc. Immuno-adjuvant pdt treatment of metastatic tumors
US20020022032A1 (en) 1999-04-23 2002-02-21 Curry Patrick Mark Immuno-adjuvant PDT treatment of metastatic tumors
US7595048B2 (en) 2002-07-03 2009-09-29 Ono Pharmaceutical Co., Ltd. Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1
WO2004006837A2 (en) 2002-07-12 2004-01-22 The Johns Hopkins University Mesothelin vaccines and model systems
US20090297540A1 (en) 2005-10-21 2009-12-03 Andrew Mellor Induction of Indoleamine 2,3-Dioxygenase in Dendritic Cells by TLR Ligands and Uses thereof
US20080318252A1 (en) 2007-04-23 2008-12-25 Scott Kachlany Rapid assay to test anti-cancer drugs under physiological conditions
GB0526033D0 (en) * 2005-12-21 2006-02-01 Bioeos Ltd Method
WO2008110491A2 (en) 2007-03-09 2008-09-18 University Of Basel Chemotherapy of neoplastic diseases using combinations of rapamycin and compounds modulating mtor pathway alone or in combination with heat
NZ600758A (en) 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
PT2172211E (pt) * 2008-10-01 2015-03-09 Immatics Biotechnologies Gmbh Composição de peptídeos associados a tumores e vacina anti -cancro relacionada para o tratamento de glioblastoma (gbm) e outros tipos de câncer
US8367075B2 (en) 2010-07-02 2013-02-05 Indian Institute Of Science Synergistic combination and method thereof
US9114158B2 (en) * 2011-03-09 2015-08-25 The Johns Hopkins University Compounds and methods of use in ablative radiotherapy
WO2012177624A2 (en) 2011-06-21 2012-12-27 The Johns Hopkins University Focused radiation for augmenting immune-based therapies against neoplasms
GB201120779D0 (en) * 2011-12-02 2012-01-11 Immodulon Therapeutics Ltd Cancer therapy
EP2620159A1 (en) 2012-01-24 2013-07-31 Institut Pasteur Improved cancer treatment by immunotherapy with bcg or antigenically related non-pathogenic mycobacteria
WO2013114367A2 (en) 2012-02-01 2013-08-08 Compugen Ltd. C10rf32 antibodies, and uses thereof for treatment of cancer
US8617520B2 (en) 2012-02-15 2013-12-31 Immodulon Therapeutics Limited Cancer therapy
GB201308325D0 (en) 2013-05-09 2013-06-19 Immodulon Therapeutics Ltd Cancer Therapy
GB201322725D0 (en) 2013-12-20 2014-02-05 Immodulon Therapeutics Ltd Cancer therapy
EP3092004A4 (en) 2014-01-06 2017-02-22 The Trustees Of The University Of Pennsylvania Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
US10975112B2 (en) 2015-06-16 2021-04-13 Hangzhou Dac Biotech Co., Ltd. Linkers for conjugation of cell-binding molecules
PL3319635T3 (pl) 2015-06-24 2021-10-25 Immodulon Therapeutics Limited Inhibitor punktu kontrolnego i prątek całokomórkowy do stosowania w terapii nowotworowej
CN112672758A (zh) 2018-06-25 2021-04-16 英摩杜伦治疗学公司 癌症治疗

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003049751A1 (en) * 2001-12-10 2003-06-19 Bakulesh Mafatlal Khamar The process of manufacturing a pharmaceutical composition useful for management of cancer
EP2010216A2 (en) * 2006-03-24 2009-01-07 Donald L. Morton Mycobacterial immunotherapy for cancer treatment

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MA X1等: ""Combination sonodynamic therapy with immunoadjuvant may be a promising new modality for cancer treatment"", 《MED HYPOTHESES》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114367060A (zh) * 2022-01-13 2022-04-19 深圳大学 激光交变电场联合治疗仪

Also Published As

Publication number Publication date
US20190224294A1 (en) 2019-07-25
RU2014121335A (ru) 2016-01-27
IL232890A0 (en) 2014-07-31
US20140356397A1 (en) 2014-12-04
BR112014012880A2 (pt) 2017-06-13
MX2014006511A (es) 2014-12-05
IN2014MN00955A (cg-RX-API-DMAC7.html) 2015-04-24
AU2012343536A1 (en) 2014-06-05
WO2013079980A1 (en) 2013-06-06
EP2785361A1 (en) 2014-10-08
JP6085611B2 (ja) 2017-02-22
AU2012343536B2 (en) 2017-08-24
JP2014533743A (ja) 2014-12-15
GB201120779D0 (en) 2012-01-11
US11318193B2 (en) 2022-05-03
US11554166B2 (en) 2023-01-17
EP2785361B1 (en) 2018-11-28
US20230149525A1 (en) 2023-05-18
NZ624994A (en) 2016-10-28
CA2857429A1 (en) 2013-06-06
US20200338181A1 (en) 2020-10-29
SG11201402396XA (en) 2014-10-30
KR20140097419A (ko) 2014-08-06

Similar Documents

Publication Publication Date Title
US20230149525A1 (en) Immunogenic treatment of cancer
Tan et al. The role of photodynamic therapy in triggering cell death and facilitating antitumor immunology
Moy et al. Combinatorial immunotherapy and nanoparticle mediated hyperthermia
JP2025185047A (ja) がんの免疫学的処置
Almeida et al. Gold nanoparticle mediated cancer immunotherapy
US9526911B1 (en) Immune mediated cancer cell destruction, systems and methods
Bai et al. Advancements and challenges in brain cancer therapeutics
JP2014533743A5 (cg-RX-API-DMAC7.html)
Séguier et al. Intratumoural immunotherapy plus focal thermal ablation for localized prostate cancer
Tranberg Local destruction of tumors and systemic immune effects
CN110478627A (zh) 一种结合石墨烯红外热疗的激光癌症治疗仪
Yan et al. Endoscopic Ultrasound‐Guided Intratumoural Therapy for Pancreatic Cancer
Guo et al. Role of endoscopic ultrasound in treatment of pancreatic cancer
Hwang et al. Endoscopic ultrasound-guided local therapy for pancreatic neoplasms
Cabuy Hyperthermia in cancer treatment
NZ624994B2 (en) Immunogenic treatment of cancer
Peng et al. Tumor therapeutic modes
Li et al. Laser immunotherapy: Concept, possible mechanism, clinical applications, and recent experimental results
Yang et al. Endoscopic Ultrasound‐Guided Therapies in Pancreatic Neoplasms
RU2530523C2 (ru) Способ противоопухолевой иммунотерапии
US20210154296A1 (en) Vaccine or immunotherapeutic agent composition containing photothermally treated cell lysates as active ingredients
CN104083205A (zh) 一种肿瘤治疗系统和方法
Testoni et al. Present and Future of Local Therapies for Unresectable Pancreatic Cancer
Campana et al. Electrochemotherapy for superficially metastatic melanoma
Vogelbaum et al. Local Therapies

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20140903

WD01 Invention patent application deemed withdrawn after publication